The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.
Danny Rischin
No relevant relationships to disclose
Daniela Matei
No relevant relationships to disclose
Jeffrey C. Goh
No relevant relationships to disclose
Michelle Margaret Vaughan
No relevant relationships to disclose
Philip James Beale
No relevant relationships to disclose
Meaghan Elizabeth Tenney
No relevant relationships to disclose
Julie Martyn
No relevant relationships to disclose
Dirkje Willemien Sommeijer
No relevant relationships to disclose
Jose Luis Iglesias
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
David C. Bibby
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Jeremy Simpson
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Elizabeth E. Doolin
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
Corinne E. Williams
No relevant relationships to disclose
Martin R. Stockler
No relevant relationships to disclose